Israel Englander Imv Inc. Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.47 - $0.75 $5,794 - $9,246	12,328 New	12,328 $6,000
Q1 2022 May 16, 2022	SELL	$1.07 - $1.5 $16,486 - $23,112	-15,408 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.78 $4,828 - $7,045	3,958 Added 34.57%	15,408 $19,000
Q3 2021 Nov 15, 2021	SELL	$1.35 - $2.16 $27,259 - $43,614	-20,192 Reduced 63.81%	11,450 $19,000
Q2 2021 Aug 16, 2021	BUY	$2.12 - $3.24 $67,081 - $102,520	31,642 New	31,642 $69,000
Q1 2021 May 17, 2021	SELL	$2.92 - $4.41 $538,599 - $813,433	-184,452 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.9 - $4.4 $439,387 - $666,657	151,513 Added 459.98%	184,452 $568,000
Q3 2020 Nov 16, 2020	BUY	$2.87 - $5.95 $94,534 - $195,987	32,939 New	32,939 $146,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.